Philips 2000 Series Air Purifier slashed to more than 40 per cent off at Amazon Australia
Air pollution is increasingly pervasive and allergy seasons are growing more intense, I know my hay fever has definitely become worse, so maintaining clean indoor air has become more important than ever.
For many, the symptoms of hay fever, asthma, and other respiratory sensitivities are no longer confined to the outdoors.
Dust, pet, airborne bacteria, and even harmful gases easily infiltrate our homes which means advanced air purification systems are no longer a luxury but a necessity.
Amazon Australia is currently offering the Philips 2000 Series Air Purifier for more than 40 per cent off, normally $389.97, it's currently on sale for $199.
This model is capable of purifying the air in a room of up to 79 square metres in less than nine minutes, delivering a clean air delivery rate (CADR) of 333 cubic metres per hour.
So if you've been feeling like your house needs a little purifying, consider this your sign to s nap up a Philips device while its on sale.
Keep your home clean
Designed with advanced filtration technology, it effectively eliminates a broad spectrum of airborne contaminants including bacteria, viruses, pet dander, harmful gases, and dust particles.
The Philips Series 2000 also has a sleep mode feature, which ensures near-silent operation during nighttime hours. This allows users to benefit from cleaner air without any disturbance to their sleep.
The air purifier also features an intelligent auto mode, which continuously monitors air quality and adjusts fan speed accordingly for optimal performance.
For users who prefer manual control, three distinct speed settings offer flexibility in tailoring both the airflow and noise levels to suit personal comfort.
Energy efficiency is another key strength of this unit. Despite its high performance, the purifier consumes a maximum of just 56 watts which comparable to the power usage of a standard household light bulb. T
his makes it an environmentally conscious choice for those wanting to maintain a healthier home environment without significantly increasing energy consumption.
Rave reviews
Shoppers have given the air purifier, a 4.6-star rating on Amazon Australia's website.
'I bought this when I had to work from home a few years ago and it has worked well and reliably ever since,' one shopper wrote.
'This is very effective,' another shopper added.
easier to breathe,' a third reviewer commented.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Advertiser
12 hours ago
- The Advertiser
Tech giant sued over sleep aid foam inhalation 'risk'
An alleged risk of patients breathing in or swallowing small particles of foam from degrading sleep aids has prompted the federal government to take legal action. Multinational health technology company Philips is accused of selling defective ventilators aimed at assisting with sleep apnoea and, after those products were recalled in June 2021, selling a further device which was also dangerous. In the lawsuit filed on Monday, the Therapeutic Goods Administration claims both sets of devices did not meet Australian safety standards. Devices sold prior to June 2021 contained a polyester-based polyurethane foam used for noise suppression. "There was a real risk of the (foam) degrading and then particulates being inhaled or ingested by the patient," the agency wrote in a statement. The potential harms from these devices included skin, eye and respiratory tract irritation, headaches, asthma and impacts on the reproductive system. Long-term exposure could damage or kill a patient's cells, cause genetic damage or cause cancer, the health watchdog alleges. "The probability of degradation, and consequential harm to the patient, was unacceptable, given the potentially serious consequences," the lawsuit claims. Philips did not conduct any risk analysis on the products until early 2021, the government agency says. Ten devices sold under the BiPAP, DreamStation, OmniLab and REMstar brands were recalled globally in June that year. After this date, Philips allegedly sold a further defective device, the Trilogy 100. This contained silicone foam which could become detached from its housing, obstructing the air path. Potential adverse health effects included increased carbon dioxide levels or low oxygen levels in the patient's blood. The TGA is seeking pecuniary penalties and orders that Philips pay its legal costs. A Philips spokeswoman said the lawsuit only revolved around the company's activities before and during the 2021 recall. "The proceeding does not make allegations about the quality and safety of products currently marketed in Australia by Philips," she said. The spokeswoman said extensive testing had been conducted internally as well as with five independent laboratories and third-party experts since June 2021. This testing concluded that the use of Philips sleep therapy devices presently sold on the market "is not expected to result in appreciable harm to health in patients". Philips would review the court documents filed by the TGA and engage constructively as required, she said. An alleged risk of patients breathing in or swallowing small particles of foam from degrading sleep aids has prompted the federal government to take legal action. Multinational health technology company Philips is accused of selling defective ventilators aimed at assisting with sleep apnoea and, after those products were recalled in June 2021, selling a further device which was also dangerous. In the lawsuit filed on Monday, the Therapeutic Goods Administration claims both sets of devices did not meet Australian safety standards. Devices sold prior to June 2021 contained a polyester-based polyurethane foam used for noise suppression. "There was a real risk of the (foam) degrading and then particulates being inhaled or ingested by the patient," the agency wrote in a statement. The potential harms from these devices included skin, eye and respiratory tract irritation, headaches, asthma and impacts on the reproductive system. Long-term exposure could damage or kill a patient's cells, cause genetic damage or cause cancer, the health watchdog alleges. "The probability of degradation, and consequential harm to the patient, was unacceptable, given the potentially serious consequences," the lawsuit claims. Philips did not conduct any risk analysis on the products until early 2021, the government agency says. Ten devices sold under the BiPAP, DreamStation, OmniLab and REMstar brands were recalled globally in June that year. After this date, Philips allegedly sold a further defective device, the Trilogy 100. This contained silicone foam which could become detached from its housing, obstructing the air path. Potential adverse health effects included increased carbon dioxide levels or low oxygen levels in the patient's blood. The TGA is seeking pecuniary penalties and orders that Philips pay its legal costs. A Philips spokeswoman said the lawsuit only revolved around the company's activities before and during the 2021 recall. "The proceeding does not make allegations about the quality and safety of products currently marketed in Australia by Philips," she said. The spokeswoman said extensive testing had been conducted internally as well as with five independent laboratories and third-party experts since June 2021. This testing concluded that the use of Philips sleep therapy devices presently sold on the market "is not expected to result in appreciable harm to health in patients". Philips would review the court documents filed by the TGA and engage constructively as required, she said. An alleged risk of patients breathing in or swallowing small particles of foam from degrading sleep aids has prompted the federal government to take legal action. Multinational health technology company Philips is accused of selling defective ventilators aimed at assisting with sleep apnoea and, after those products were recalled in June 2021, selling a further device which was also dangerous. In the lawsuit filed on Monday, the Therapeutic Goods Administration claims both sets of devices did not meet Australian safety standards. Devices sold prior to June 2021 contained a polyester-based polyurethane foam used for noise suppression. "There was a real risk of the (foam) degrading and then particulates being inhaled or ingested by the patient," the agency wrote in a statement. The potential harms from these devices included skin, eye and respiratory tract irritation, headaches, asthma and impacts on the reproductive system. Long-term exposure could damage or kill a patient's cells, cause genetic damage or cause cancer, the health watchdog alleges. "The probability of degradation, and consequential harm to the patient, was unacceptable, given the potentially serious consequences," the lawsuit claims. Philips did not conduct any risk analysis on the products until early 2021, the government agency says. Ten devices sold under the BiPAP, DreamStation, OmniLab and REMstar brands were recalled globally in June that year. After this date, Philips allegedly sold a further defective device, the Trilogy 100. This contained silicone foam which could become detached from its housing, obstructing the air path. Potential adverse health effects included increased carbon dioxide levels or low oxygen levels in the patient's blood. The TGA is seeking pecuniary penalties and orders that Philips pay its legal costs. A Philips spokeswoman said the lawsuit only revolved around the company's activities before and during the 2021 recall. "The proceeding does not make allegations about the quality and safety of products currently marketed in Australia by Philips," she said. The spokeswoman said extensive testing had been conducted internally as well as with five independent laboratories and third-party experts since June 2021. This testing concluded that the use of Philips sleep therapy devices presently sold on the market "is not expected to result in appreciable harm to health in patients". Philips would review the court documents filed by the TGA and engage constructively as required, she said. An alleged risk of patients breathing in or swallowing small particles of foam from degrading sleep aids has prompted the federal government to take legal action. Multinational health technology company Philips is accused of selling defective ventilators aimed at assisting with sleep apnoea and, after those products were recalled in June 2021, selling a further device which was also dangerous. In the lawsuit filed on Monday, the Therapeutic Goods Administration claims both sets of devices did not meet Australian safety standards. Devices sold prior to June 2021 contained a polyester-based polyurethane foam used for noise suppression. "There was a real risk of the (foam) degrading and then particulates being inhaled or ingested by the patient," the agency wrote in a statement. The potential harms from these devices included skin, eye and respiratory tract irritation, headaches, asthma and impacts on the reproductive system. Long-term exposure could damage or kill a patient's cells, cause genetic damage or cause cancer, the health watchdog alleges. "The probability of degradation, and consequential harm to the patient, was unacceptable, given the potentially serious consequences," the lawsuit claims. Philips did not conduct any risk analysis on the products until early 2021, the government agency says. Ten devices sold under the BiPAP, DreamStation, OmniLab and REMstar brands were recalled globally in June that year. After this date, Philips allegedly sold a further defective device, the Trilogy 100. This contained silicone foam which could become detached from its housing, obstructing the air path. Potential adverse health effects included increased carbon dioxide levels or low oxygen levels in the patient's blood. The TGA is seeking pecuniary penalties and orders that Philips pay its legal costs. A Philips spokeswoman said the lawsuit only revolved around the company's activities before and during the 2021 recall. "The proceeding does not make allegations about the quality and safety of products currently marketed in Australia by Philips," she said. The spokeswoman said extensive testing had been conducted internally as well as with five independent laboratories and third-party experts since June 2021. This testing concluded that the use of Philips sleep therapy devices presently sold on the market "is not expected to result in appreciable harm to health in patients". Philips would review the court documents filed by the TGA and engage constructively as required, she said.
9 News
14 hours ago
- 9 News
Tech giant sued over risk from sleeping aids
Your web browser is no longer supported. To improve your experience update it here An alleged risk of patients breathing in or swallowing small particles of foam from degrading sleep aids has prompted the federal government to take legal action. Multinational health technology company Philips is accused of selling defective ventilators aimed at assisting with sleep apnoea and, after those products were recalled in June 2021, selling a further device which was also dangerous. In the lawsuit filed yesterday, the Therapeutic Goods Administration claims both sets of devices did not meet Australian safety standards. An alleged risk of patients breathing in or swallowing small particles of foam from degrading sleep aids has prompted the federal government to take legal action. (Getty Images/iStockphoto) Devices sold prior to June 2021 contained a polyester-based polyurethane foam used for noise suppression. "There was a real risk of the (foam) degrading and then particulates being inhaled or ingested by the patient," the agency wrote in a statement. The potential harms from these devices included skin, eye and respiratory tract irritation, headaches, asthma and impacts on the reproductive system. Long-term exposure could damage or kill a patient's cells, cause genetic damage or cause cancer, the health watchdog alleges. "The probability of degradation, and consequential harm to the patient, was unacceptable, given the potentially serious consequences," the lawsuit claims. Philips did not conduct any risk analysis on the products until early 2021, the government agency says. Ten devices sold under the BiPAP, DreamStation, OmniLab and REMstar brands were recalled globally in June that year. After this date, Philips allegedly sold a further defective device, the Trilogy 100. This contained silicone foam which could become detached from its housing, obstructing the air path. Potential adverse health effects included increased carbon dioxide levels or low oxygen levels in the patient's blood. The TGA is seeking pecuniary penalties and orders that Philips pay its legal costs. A Philips spokeswoman said the lawsuit only revolved around the company's activities before and during the 2021 recall. "The proceeding does not make allegations about the quality and safety of products currently marketed in Australia by Philips," she said. The spokeswoman said extensive testing had been conducted internally as well as with five independent laboratories and third-party experts since June 2021. This testing concluded that the use of Philips sleep therapy devices presently sold on the market "is not expected to result in appreciable harm to health in patients". Philips would review the court documents filed by the TGA and engage constructively as required, she said. national Australia courts Sydney New South Wales Technology Tech CONTACT US
West Australian
15 hours ago
- West Australian
Tech giant sued over sleep aid foam inhalation 'risk'
An alleged risk of patients breathing in or swallowing small particles of foam from degrading sleep aids has prompted the federal government to take legal action. Multinational health technology company Philips is accused of selling defective ventilators aimed at assisting with sleep apnoea and, after those products were recalled in June 2021, selling a further device which was also dangerous. In the lawsuit filed on Monday, the Therapeutic Goods Administration claims both sets of devices did not meet Australian safety standards. Devices sold prior to June 2021 contained a polyester-based polyurethane foam used for noise suppression. "There was a real risk of the (foam) degrading and then particulates being inhaled or ingested by the patient," the agency wrote in a statement. The potential harms from these devices included skin, eye and respiratory tract irritation, headaches, asthma and impacts on the reproductive system. Long-term exposure could damage or kill a patient's cells, cause genetic damage or cause cancer, the health watchdog alleges. "The probability of degradation, and consequential harm to the patient, was unacceptable, given the potentially serious consequences," the lawsuit claims. Philips did not conduct any risk analysis on the products until early 2021, the government agency says. Ten devices sold under the BiPAP, DreamStation, OmniLab and REMstar brands were recalled globally in June that year. After this date, Philips allegedly sold a further defective device, the Trilogy 100. This contained silicone foam which could become detached from its housing, obstructing the air path. Potential adverse health effects included increased carbon dioxide levels or low oxygen levels in the patient's blood. The TGA is seeking pecuniary penalties and orders that Philips pay its legal costs. A Philips spokeswoman said the lawsuit only revolved around the company's activities before and during the 2021 recall. "The proceeding does not make allegations about the quality and safety of products currently marketed in Australia by Philips," she said. The spokeswoman said extensive testing had been conducted internally as well as with five independent laboratories and third-party experts since June 2021. This testing concluded that the use of Philips sleep therapy devices presently sold on the market "is not expected to result in appreciable harm to health in patients". Philips would review the court documents filed by the TGA and engage constructively as required, she said.
